论文部分内容阅读
目的观察同种异体肾移植术前血液透析治疗的尿毒症患者应用重组人红细胞生成素(rHuEPO)对肾性贫血的临床疗效。方法232例患者均采用rHuEPO;初始每次50-100u/kg,每周2次,皮下注射或静脉注射,检测治疗前,治疗后4周以及治疗后8周血红蛋白,红细胞计数、红细胞压积、血小板、尿素氮、血肌酐、尿酸、血清钾、血清钠、血清氯、有机磷等,并随机记录患者出现的各种不良反应。结果显效153例(66%),有效66例(29%),无效13例(5%)。总有效率94.3%。rHuEPO不良反应主要是高血压(12%)、注射部位疼痛(3.8%)等。结论肾移植术前尿毒症期患者应在充分透析的前提下,采用大剂量国产rHuEPO治疗贫血安全,有效。可靠。耗资低且手术成功率高提高,副作用小,值得临床推广。
Objective To observe the clinical effect of recombinant human erythropoietin (rHuEPO) on renal anemia in uremic patients treated with hemodialysis before renal transplantation. Methods A total of 232 patients were enrolled in this study. Each group received rHuEPO 50-100u / kg twice a week by subcutaneous injection or intravenous injection. The levels of hemoglobin, erythrocyte count, hematocrit, Platelets, urea nitrogen, serum creatinine, uric acid, serum potassium, serum sodium, serum chlorine, organophosphorus and so on, and randomly recorded the patient’s various adverse reactions. The results were markedly effective in 153 cases (66%), effective in 66 cases (29%), ineffective in 13 cases (5%). The total efficiency of 94.3%. Adverse reactions of rHuEPO were mainly hypertension (12%), injection site pain (3.8%) and so on. Conclusions Patients with uremia prior to renal transplantation should be safe and effective in treating anemia with large doses of domestic rHuEPO under the premise of adequate dialysis. reliable. Low cost and high success rate of surgery, side effects, worthy of clinical promotion.